TY  - JOUR
T1  - Myricetin can control metastasis and invasion by suppressing ATF2-related signaling pathway in Rapamycin-resistant HepG2 hepatocellular cancer cells
AU  - Erdoğan, Ömer
AU  - Çevik, Özge
PY  - 2025
DA  - June
JF  - Journal of Research in Pharmacy
JO  - J. Res. Pharm.
PB  - Marmara University
WT  - DergiPark
SN  - 2630-6344
SP  - 557
EP  - 565
VL  - 27
IS  - 2
LA  - en
AB  - Hepatocellular carcinoma continues to be one of the major health problems. One of the most importantchallenges in the treatment of hepatocellular cancer is gaining resistance to chemotherapy. Therefore, there is an urgentneed for discoveries of naturally occurring antitumor compounds in the diet and to elucidate the anticancer mechanismsof action of existing dietary origin compounds. Myricetin is a dietary flavonoid and its antitumor activity is reported.In this study, HepG2 cells were incubated with 100 nM rapamycin for 6 weeks to develop rapamycin resistance. 10, 100,250 and 500 µM myricetin was applied to rapamycin resistant HepG2 human hepatocellular cancer cells (HepG2-RR)for 24 and 48 hours. Changes in ATF2, SMAD3, SMAD4 and Col1A1 expressions of HepG2-RR cells after myricetinapplication were evaluated by Western blot and qPCR analysis. In addition, the effect of myricetin treatment on themigration/invasion of HepG2-RR cells was specified using the BD 24-well Boyden chamber. The IC50 values ofrapamycin and myricetin on HepG2 cells for 48 hours incubation was calculated as 89,03±6,14 nM and 126,25±7,32 µM,respectively. On the other hand, we found that HepG2-RR cells treated with myricetin decreased cell proliferation,invasion, and migration by reducing the expression of ATF2, SMAD3, SMAD4, and Col1A1. As a result, we were shownthat myricetin administration inhibited cell growth and cell migration by suppressing ATF2 in hepatocellular carcinomacells that gained drug resistance.
KW  - Myricetin
KW  - Rapamycin
KW  - Liver Cancer
KW  - Metastasis
CR  - Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal
for clinicians. 2021; 71(3): 209-249. https://doi.org/10.3322/caac.21660
CR  - Liu CY, Chen KF, Chen PJ. Treatment of liver cancer. Cold Spring Harbor perspectives in medicine. 2015; (9): a021535.
Anwanwan D, Singh, SK, Singh S, Saikam V, Singh R. Challenges in liver cancer and possible treatment approaches.
Biochimica et Biophysica Acta (BBA)-Reviews on Cancer. 2020; 1873(1): 188314.
https://doi.org/10.1016/j.bbcan.2019.188314
CR  - Bhoumik A, Lopez‐Bergami P, Ronai ZE. ATF2 on the double–activating transcription factor and DNA damage
response protein. Pigment Cell Research. 2007; 20(6): 498-506. https://doi.org/10.1111/j.1600-0749.2007.00414.x
CR  - Bao ZM, Yao D, Qian X, Zhang HG, Yang M, Guo YH, Qin L. (2022). Activating transcription factor 2 promotes the
progression of hepatocellular carcinoma by inducing the activation of the WHSC1‐mediated TOP2A/PI3K/AKT
axis. The Kaohsiung Journal of Medical Sciences. 2022; 1-13. https://doi.org/10.1002/kjm2.12536
CR  - Luo L, Cai L, Luo L, Tang Z, Meng X. Silencing activating transcription factor 2 promotes the anticancer activity of
sorafenib in hepatocellular carcinoma cells. Molecular medicine reports. 2018; 17(6): 8053-8060.
https://doi.org/10.3892/mmr.2018.8921
CR  - Sarbassov DD, Ali SM, Sabatini DM. Growing roles for the mTOR pathway. Current opinion in cell biology. 2005;
17(6); 596-603. https://doi.org/10.1016/j.ceb.2005.09.009
CR  - Sarbassov DD, Ali SM, Sengupta S, Sheen, JH, Hsu PP, Bagley AF, Sabatini DM. Prolonged rapamycin treatment
inhibits mTORC2 assembly and Akt/PKB. Molecular cell. 2006; 22(2): 159-168.
https://doi.org/10.1016/j.molcel.2006.03.029
CR  - Guertin DA, Sabatini DM. An expanding role for mTOR in cancer. Trends Mol. Med. 2005; 11: 353–361.
https://doi.org/10.1016/j.molmed.2005.06.007
CR  - Polivka J, Janku F. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. Pharmacology &
therapeutics. 2014: 142(2); 164-175. https://doi.org/10.1016/j.pharmthera.2013.12.004
CR  - Devi KP, Rajavel T, Habtemariam S, Nabavi SF, Nabavi SM. Molecular mechanisms underlying anticancer effects of
myricetin. Life sciences. 2015; 142: 19-25. https://doi.org/10.1016/j.lfs.2015.10.004
CR  - Li C, Lim SC, Kim J, Choi JS. Effects of myricetin, an anticancer compound, on the bioavailability and
pharmacokinetics of tamoxifen and its main metabolite, 4-hydroxytamoxifen, in rats. European journal of drug
metabolism and pharmacokinetics. 2011: 36(3); 175-182. https://doi.org/10.1007/s13318-011-0036-y
CR  - Gorshtein A, Rubinfeld H, Kendler E, Theodoropoulou M, Cerovac V, Stalla GK, Shimon I. (2009). Mammalian target
of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting
pituitary tumor cells in vitro. Endocrine-related cancer. 2009: 16(3); 1017-1027. https://doi.org/10.1677/ERC-08-0269
CR  - Koike H, Nitta T, Sekine Y, Arai S, Furuya Y, Nomura M, Suzuki K. (2014). YM155 reverses rapamycin resistance in
renal cancer by decreasing survivin. Journal of cancer research and clinical oncology. 2014: 140; 1705-1713.
https://doi.org/10.1007/s00432-014-1734-z
CR  - Tian X, Dai S, Sun J, Jiang S, Sui C, Meng F, Jiang Y. Inhibition of MDM2 re-sensitizes rapamycin resistant renal cancer
cells via the activation of p53. Cellular Physiology and Biochemistry. 2016: 39(5); 2088-2098.
https://doi.org/10.1159/000447904
CR  - Li QL, Gu FM, Wang Z, Jiang JH, Yao LQ, Tan CJ, Zhou J. Activation of PI3K/AKT and MAPK pathway through a
PDGFRβ-dependent feedback loop is involved in rapamycin resistance in hepatocellular carcinoma. PLoS One. 2012:
7(3); e33379. https://doi.org/10.1371/journal.pone.0033379
CR  - Zugazagoitia J, Guedes C, Ponce S, Ferrer I, Molina-Pinelo S, Paz-Ares L. Current challenges in cancer treatment.
Clinical therapeutics. 2016; 38(7): 1551-1566. https://doi.org/10.1016/j.clinthera.2016.03.026
CR  - Sun F, Zheng XY, Ye J, Wu TT, Wang JL, Chen W. Potential anticancer activity of myricetin in human T24 bladder
cancer cells both in vitro and in vivo. Nutrition and cancer. 2012: 64(4); 599-606.
https://doi.org/10.1080/01635581.2012.665564
CR  - Neuzillet C, Tijeras-Raballand A, de Mestier L, Cros J, Faivre S, Raymond E. MEK in cancer and cancer therapy.
Pharmacol. Ther. 2014: 141; 160–171. https://doi.org/10.1016/j.pharmthera.2013.10.001
CR  - Lee KW, Kang NJ, Rogozin EA, Kim HG, Cho YY, Bode AM, Dong Z. Myricetin is a novel natural inhibitor of
neoplastic cell transformation and MEK1. Carcinogenesis, 2007: 28(9); 1918-1927.
https://doi.org/10.1093/carcin/bgm110
CR  - Derynck R, Akhurst RJ, Balmain A. TGF-b signaling in tumor suppression and cancer progression. Nat. Genet. 2001;
29; 117–129. https://doi.org/10.1038/ng1001-117
CR  - Tang PMK, Zhou S, Meng XM, Wang QM, Li CJ, Lian GY, Lan HY. Smad3 promotes cancer progression by inhibiting
E4BP4-mediated NK cell development. Nature communications. 2017: 8(1); 1-15.
https://doi.org/10.1038/ncomms14677
CR  - Alhopuro P, Alazzouzi H, Sammalkorpi H, Dávalos V, Salovaara R, Hemminki A, Arango D. (2005). SMAD4 levels
and response to 5-fluorouracil in colorectal cancer. Clinical Cancer Research. 2005: 11(17); 6311-6316.
https://doi.org/10.1158/1078-0432.CCR-05-0244
CR  - Li J, Ding Y, Li A. Identification of COL1A1 and COL1A2 as candidate prognostic factors in gastric cancer. World
journal of surgical oncology. 2016: 14(1); 1-5. https://doi.org/10.1186/s12957-016-1056-5
CR  - Liu S, Liao G, Li G. Regulatory effects of COL1A1 on apoptosis induced by radiation in cervical cancer cells. Cancer
cell international. 2017: 17(1); 1-9. https://doi.org/10.1186/s12935-017-0443-5
CR  - Zhao W, Jiang X, Yang, S. lncRNA TUG1 promotes cell proliferation, migration, and invasion in hepatocellular
carcinoma via regulating miR-29c-3p/COL1A1 axis. Cancer Management and Research. 2020: 12; 6837.
https://doi.org/10.2147/CMAR.S256624
CR  - Gumus E, Erdogan O, Demirkan B, Cevik O. Squalene suppresses Jam-A, Claudin 5, and Occludin by accelerating
cell death and reducing neuronal interaction in the neuroblastoma cell line SH-SY5Y. Journal of Research in
Pharmacy. 2022: 26(6); 1676-1684. http://dx.doi.org/10.29228/jrp.258
CR  - Erdogan O, Abbak M, Demirbolat GM, Birtekocak F, Aksel M, Pasa S, Cevik, O. (2019). Green synthesis of silver
nanoparticles via Cynara scolymus leaf extracts: The characterization, anticancer potential with photodynamic
therapy in MCF7 cells. PloS one. 2019: 14(6); e0216496. https://doi.org/10.1371/journal.pone.0216496
CR  - Paşa S, Erdogan O, Cevik O. Design, synthesis and investigation of procaine based new Pd complexes as DNA
methyltransferase inhibitor on gastric cancer cells. Inorganic Chemistry Communications. 2021: 132; 108846.
https://doi.org/10.1016/j.inoche.2021.108846
CR  - Cevik O, Li D, Baljinnyam E, Manvar D, Pimenta EM, Waris G, Kaushik-Basu, N. Interferon regulatory factor 5 (IRF5)
suppresses hepatitis C virus (HCV) replication and HCV-associated hepatocellular carcinoma. Journal of Biological
Chemistry. 2017: 292(52); 21676-21689. https://doi.org/10.1074/jbc.M117.792721
UR  - https://dergipark.org.tr/en/pub/jrespharm/issue//1690367
L1  - https://dergipark.org.tr/en/download/article-file/4832632
ER  -